Schizoaffective Disorder: Clinical Trials

62 trials for Schizoaffective Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 7 terminated, 3 unknown, 1 recruiting. 62 Phase 2, 8 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 262Completed 49, Terminated 7, Unknown 3, Recruiting 1, Suspended 1, Withdrawn 1
Phase 18Completed 6, Suspended 1, Terminated 1
Phase 37Completed 7

Follow Schizoaffective Disorder: new trials by email Literature Review of Schizoaffective Disorder trials Research Report on Schizoaffective Disorder

Trials (filtered) newest first · largest first

All 62 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder
Phase 2CompletedBioXcel Therapeutics Inc332025-06-192026-10-05
Accelerated TMS in Psychosis
repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2SuspendedBeth Israel Deaconess Medical Center202022-11-292026-04-22
Sodium Nitroprusside in Early Course Schizophrenia
Sodium Nitroprusside, 5% Dextrose solution - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedBeth Israel Deaconess Medical Center12022-03-142025-12-30
Synbiotic Compound to Reduce Symptoms of Schizophrenia
Synbiotic Supplement, Inert Compound - Schizophrenia, Schizoaffective Disorder
Phase 2RecruitingSheppard Pratt Health System682022-02-212026-04-07
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Memantine, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2 / Phase 3CompletedUniversity of California, San Diego622021-07-062026-05-18
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
d-amphetamine, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedUniversity of California, San Diego682020-11-092025-12-17
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
N-acetylcysteine (NAC), Placebo, Tryptophan - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2CompletedUniversity of Maryland, Baltimore882020-01-202026-02-11
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
Sodium Benzoate, N-Acetylcysteine, Placebo - Schizophrenia, Schizophreniform Disorders
Phase 2CompletedPakistan Institute of Living and Learning642019-01-012022-04-27
Sulforaphane to Reduce Symptoms of Schizophrenia
Sulforaphane Nutraceutical, Identical-appearing Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedSheppard Pratt Health System642017-02-222021-07-27
Cannabidiol Treatment in Patients With Early Psychosis
Cannabidiol, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedYale University182016-01-282022-09-06
Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
Meclofenamic acid, Pentosan polysulfate sodium - Psychotic Disorders, Schizophrenia
Phase 2CompletedThe University of Texas Health Science Center, Houston82015-08-072019-03-26
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Aripiprazole, Olanzapine, Paliperidone - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedJanssen Research & Development, LLC92015-05-012017-03-29
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
Cholecalciferol, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2WithdrawnNYU Langone Health2015-02-012015-10-12
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
Galantamine ER, Memantine XR - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedSheppard Pratt Health System32014-09-012017-11-09
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
MMFS-202-302, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedNorthwestern University602014-08-012025-06-22
Effectiveness of Adherence Therapy for Schizophrenia
Adherence therapy - Schizophrenia, Schizophreniform Disorder
Phase 1 / Phase 2CompletedThe Hong Kong Polytechnic University1342013-05-012016-02-19
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Latuda© - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedUniversity of North Carolina, Chapel Hill92012-12-012017-06-14
Kuvan in People With Schizophrenia and Schizoaffective Disorder
Kuvan, Multivitamin - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2CompletedNew York State Psychiatric Institute272012-10-012017-09-13
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
Pipamperone, Placebo - Chronic Schizophrenia, Schizoaffective Disorder
Phase 2CompletedPharmaNeuroBoost N.V.72012-03-012014-11-19
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
D-serine, placebo, Sensory Based remediation paradigm - Schizophrenia, Schizoaffective Disorder
Phase 2UnknownNathan Kline Institute for Psychiatric Research162012-03-012012-10-25

Showing 20 of 62. Sign in to see all of them.

Narrower conditions

Psychotic Disorders (62)  ·  Schizophrenia (58)  ·  Bipolar Disorder (11)  ·  Mental Disorders (5)  ·  Smoking (3)  ·  Cognitive Dysfunction (2)  ·  Depression (2)  ·  Mania (2)  ·  Mood Disorders (2)  ·  Obesity (2)  ·  Smoking Cessation (2)  ·  Affective Disorders, Psychotic (1)  ·  Asperger Syndrome (1)  ·  Autism Spectrum Disorder (1)  ·  Autistic Disorder (1)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (62)  ·  Mental Disorders (57)  ·  Bipolar and Related Disorders (11)  ·  Behavior (9)  ·  Mood Disorders (9)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Signs and Symptoms (6)  ·  Nervous System Diseases (5)  ·  Neurologic Manifestations (5)  ·  Behavioral Symptoms (4)  ·  Neurobehavioral Manifestations (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Metabolic Diseases (3)  ·  Body Weight (2)  ·  Cardiovascular Diseases (2)

Interventions

Estradiol (3)  ·  bifeprunox (3)  ·  Acetylcysteine (2)  ·  Aripiprazole (2)  ·  Cannabidiol (2)  ·  Memantine (2)  ·  Olanzapine (2)  ·  Paliperidone Palmitate (2)  ·  Quetiapine Fumarate (2)  ·  Risperidone (2)  ·  Therapeutics (2)  ·  Transcranial Magnetic Stimulation (2)  ·  ziprasidone (2)  ·  3-(2,4-dimethoxybenzylidene)anabaseine (1)  ·  Asian ginseng (1)

Sponsors

Nathan Kline Institute for Psychiatric Research (3)  ·  Sheppard Pratt Health System (3)  ·  Solvay Pharmaceuticals (3)  ·  The Alfred (3)  ·  University of Maryland, Baltimore (3)  ·  University of Pittsburgh (3)  ·  VA Office of Research and Development (3)  ·  Beth Israel Deaconess Medical Center (2)  ·  Manhattan Psychiatric Center (2)  ·  New York State Psychiatric Institute (2)  ·  Pakistan Institute of Living and Learning (2)  ·  US Department of Veterans Affairs (2)  ·  University of California, San Diego (2)  ·  Yale University (2)  ·  Bayside Health (1)

Countries

United States (46)  ·  Australia (4)  ·  Israel (3)  ·  Canada (2)  ·  Pakistan (2)  ·  Belgium (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  India (1)  ·  Malaysia (1)  ·  Moldova (1)  ·  Norway (1)  ·  Philippines (1)  ·  Puerto Rico (1)  ·  Romania (1)

Top investigators

Jayashri Kulkarni, MBBS, MPM, FRANZCP, PhD (3)  ·  Faith Dickerson, PhD, MPH (2)  ·  Aaron T Beck, MD (1)  ·  Alan Breier, MD (1)  ·  Amy L Drapalski, PhD (1)  ·  Andreas Bechdolf, PD Dr. (1)  ·  Andrew Cutler, MD (1)  ·  Arielle D. Stanford, MD (1)  ·  Armando J Rotondi (1)  ·  Beth L Murphy, MD/PhD (1)  ·  BioXcel MM (1)  ·  Brian A Fallon, MD (1)  ·  Christine Marx, MD MA (1)  ·  Daniel C Javitt, MD, PhD (1)

Results publications

PMID 11483142, PMID 12823166, PMID 15870612, PMID 16095473, PMID 16131943, PMID 16571581, PMID 16680620, PMID 16737798, PMID 17898352, PMID 18678800, PMID 19818257, PMID 20810586, PMID 21346616, PMID 21969420, PMID 22446565, PMID 22795211, PMID 23782463, PMID 25313530, PMID 26072311, PMID 26457385, PMID 26911397, PMID 27089154, PMID 28318835, PMID 28705532, PMID 28825423, PMID 29619533, PMID 30542300, PMID 31233321, PMID 31414842, PMID 33234053, PMID 33609856, PMID 34817851, PMID 35395548, PMID 36892916, PMID 39144112

NIH funding

P50MH086383 (1), R01MH059807 (1), R01MH061412 (1), R01MH063484 (1), R01MH072556 (1), R21DA030763 (1)